Stocks Charging Up for Historic Highs: Boston Scientific (NYSE:BSX), Horizon Pharma (NASDAQ:HZNP)

Boston Scientific Corporation (NYSE:BSX) runs in leading trade, it inching up 0.84% to traded at $21.66. BSX attains analyst recommendation of 1.80 on scale of 1-5 with week’s performance of 1.27%. Per its plan, medical device major Boston Scientific Corporation BSX recently completed the acquisition of specialty medical device company Neovasc Inc.’s NVCN tissue processing technology and facility for $67.9 million. The company also acquired 15% equity interest in Neovasc for $7.1 million.

To find out the technical position of BSX, it holds price to book ratio of 4.51 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 17.09, and price to earnings ratio calculated as 376.84. The price to earnings growth ration calculated as 30.37. BSX is presenting price to cash flow of 122.61 and free cash flow concluded as 104.90.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -98.30%, and looking further price to next year’s EPS is 14.07%. While take a short look on price to sales ratio, that was 3.56 and price to earning ration of 376.84 attracting passive investors.

Horizon Pharma plc (NASDAQ:HZNP) kept active in under and overvalue discussion, HZNP holds price to book ratio of 1.89 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.

Fundament/ News Factor in Focus

Taking look on ratio analysis, HZNP has forward price to earnings ratio of 6.53. The co is presenting price to cash flow as 4.69 and while calculating price to free cash flow it concluded at 7.41, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 4.85% for a week and 4.95% for a month. Its beta stands at 1.61 times. Narrow down four to firm performance, its weekly performance was 5.96% and monthly performance was -25.41%.


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *